Actelion

Dice Therapeutics, Inc is a biopharmaceutical company based in South San Francisco, CA, dedicated to developing innovative oral medicines for autoimmune and inflammatory diseases. With a focus on biologically validated targets in immunology, they are building a robust pipeline of high-impact oral therapeutic candidates, including their lead program targeting the IL-17 cytokine for psoriasis and other IL-17 mediated diseases. Driven by a passion for innovation and backed by extensive experience in small molecule drug discovery and development, Dice Therapeutics aims to revolutionize the treatment landscape for chronic autoimmune and inflammatory diseases. Their DELSCAPE platform is designed to identify selective oral small molecules that modulate protein-protein interactions as effectively as systemic biologics, offering more convenient and accessible treatment options for patients.Generated from the website